
|Videos|December 1, 2022
COMING SOON: The Role of BCMA-Directed Therapy in Relapsed/Refractory Multiple Myeloma
Author(s)Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP, provides a look at an upcoming Virtual Tumor Board program on BCMA-directed therapies in relapsed/refractory multiple myeloma treatment.
Advertisement
Episodes in this series

Now Playing
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5



























